PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jbcThe Journal of Biological Chemistry
 
J Biol Chem. 2016 January 15; 291(3): 1368–1386.
Published online 2015 November 18. doi:  10.1074/jbc.M115.684795
PMCID: PMC4714221

FcγRIIIa-Syk Co-signal Modulates CD4+ T-cell Response and Up-regulates Toll-like Receptor (TLR) Expression*An external file that holds a picture, illustration, etc.
Object name is sbox.jpg

Abstract

CD4+ T-cells in systemic lupus erythematosus (SLE) patients show altered T-cell receptor signaling, which utilizes Fc-receptor γ-chain FcRγ-Syk. A role for FcγRIIIa activation from immune complex (IC) ligation and sublytic terminal complement complex (C5b-9) in CD4+ T-cell responses is not investigated. In this study, we show that the ICs present in SLE patients by ligating to FcγRIIIa on CD4+ T-cells phosphorylate Syk and provide a co-stimulatory signal to CD4+ T-cells in the absence of CD28 signal. This led to the development of pathogenic IL-17A+ and IFN-γhigh CD4+ T-cells in vitro. Cytokines IL-1β, IL-6, TGF-β1, and IL-23 were the only requirement for the development of both populations. SLE patients CD4+ T-cells that expressed CD25, CD69, and CD98 bound to ICs showed pSyk and produced IFN-γ and IL-17A. This FcγRIIIa-mediated co-signal differentially up-regulated the expression of IFN pathway genes compared with CD28 co-signal. FcγRIIIa-pSyk up-regulated several toll-like receptor genes as well as the HMGB1 and MyD88 gene transcripts. ICs co-localized with these toll-like receptor pathway proteins. These results suggest a role for the FcγRIIIa-pSyk signal in modulating adaptive immune responses.

Keywords: autoimmunity, Fc-γ receptor, interferon, T helper cells, toll-like receptor (TLR)

Introduction

Concurrent with the presence of aberrant T-cell responses, elevated serum levels of both immune complexes (ICs)2 and C5b-9 (non-lytic terminal complement complex) are associated with systemic lupus erythematosus (SLE) (1, 2). These immune-reactants form immune deposits at vascular sites and trigger inflammation (3). Immune deposits are also present in the ectopic germinal centers, the site for plasma B cell development (4). Formation of ICs by autoantibodies activate complement cascade and drive the formation of C5b-9 on cell membrane. We previously showed that non-lytic C5b-9 deposits trigger clustering of membrane rafts (MRs) observed in SLE T-cells. Hence, we examined the role for FcγRIIIa ligation by ICs in CD4+ T-cell responses in the presence of sublytic C5b-9 (5, 6).

T-cell receptor (TCR) engagement with peptide-MHC (pMHC) and a co-stimulation by CD28 is required for CD4+ T-cell activation and differentiation into effector CD4+ T-cells (TE). This requirement of CD28 in the periphery varies based on anatomical location, stage of immune response, nature of T-cell subsets, and the activation status of the CD4+ T-cells (7,9). CD28 co-signal is a quantitative signal that overcomes the signal threshold necessary for T-cell activation, otherwise unattainable by the TCR ligation alone (10). In an autoimmune background, T-cell activation occurs without the requirement of CD28 co-signal (10). The mechanisms that drive this activation are unknown. A sublytic C5b-9 deposit trigger MR clustering, a function attributed to CD28 co-signaling (11). Naïve CD4+ T-cells treated with ICs and C5b-9 phosphorylate TCR signaling proteins and spleen tyrosine kinase (Syk) (11). The external and internal stimuli that trigger helper CD4+ T-cell (TH) differentiation and lineage commitment in autoimmunity still remain unclear (10, 12,15).

FcRγ chain signaling unit of FcγRIIIa displaces the CD3ζ chain in TCR-CD3 complex in SLE T-cells (16). FcRγ chain signals via Syk and is a stronger signal than ζ-chain-ZAP-70. ZAP-70-deficient patients express and signal via Syk. Sykhigh/ZAP-70 T-cells show decreased Erk, JNK, and MAPK activity, suggesting a distinct signaling (17). TE cells in SLE patients show up-regulation of FcRγ-Syk signaling (18).

TE populations, TH1, and TH17 that produce interferon-γ (IFN-γ) and interleukin-17 (IL-17) contribute to autoimmune pathology (19, 20). IFN-γ is a key cytokine that influences several immune processes (19, 21). IFN-γ supports antibody production via several pathways including enhanced MHC expression (19, 22). IFN-γ influences chromatin remodeling and enhance accumulation of follicular helper T-cells (TFH) population during the formation of ectoid lymphoid follicles (23, 24). The IFN-inducible gene signature is observed in rheumatoid arthritis (RA) and SLE and serves as a marker for disease severity in SLE (25,27).

Although the TH1 response initiates tissue damage, TH17 responses sustain tissue injuries during organ-specific autoimmunity, such as in synovium, heart, skin, and brain, which are also often the site of immune deposits. TH17 responses are observed both in inflammation and in autoimmunity (20, 28). IL-17 cytokines are necessary for the development of severe glomerulonephritis (29). Pathogenic TH17 cell commitment has a unique requirement of IL-23 that is elevated in serum and tissue in SLE patients (30). Both IFN-γ and IL-17A are therapeutic target for intervention in many autoimmune disease conditions (31,33).

Toll-like receptor (TLR) signaling in innate cells indirectly promotes T-cell differentiation. T-cells express TLRs and promote cytokine secretion. TLR signaling augments the TH1, TH17, and Tregs responses (34, 35). Activation of TLRs by DNA/RNA-ICs leads to autoantibody production. FcγRII (CD32) is a key participant for the delivery of DNA-ICs to many cell types (36). Subcellular localization of TLR9 discriminate between self and non-self DNA (37).

In this report, we demonstrate that the FcγRIIIa-pSyk signal successfully replaced the CD28 requirement for differentiation of CD4+ T-cells. ICs ligation to FcγRIIIa phosphorylates Syk (pSyk), which caused the activation of CD4+ T-cells. In the presence of polarizing cytokines, this activation resulted in the development of CD4+IFN-γhigh and IL-17A-producing subsets. FcγRIIIa-pSyk co-signal induced colony stimulating factor 2 (Csf2) and IL-2 gene expression, which are associated with pathogenic TH17 cells. In SLE patients, CD4+ T-cell showed a subset that expressed activation markers CD25, CD69, and CD98, which also bound to ICs and showed pSyk. Furthermore, these activated cells produced IFN-γ and IL-17A. FcγRIIIa-pSyk-mediated signal differentially regulated the expression of IFN pathway genes. Co-signaling triggered by IC ligation of FcγRIIIa up-regulated expression of TLR signaling genes, suggesting a co-operation among these pathways.

Experimental Procedures

Subjects

Blood from SLE patients and normal donors was collected with informed consent in the Saint Louis University Rheumatology clinic. The peripheral blood mononuclear cells were isolated using the Histopaque gradient (Sigma). The donors 1–9 were analyzed for IFN-γ and IL-17A (Figs. 1 and and2).2). IL-21 production was analyzed in donors 1–4. This analysis from these donors is presented in Figs. 1, ,2,2, and and4.4. Donors 8, 9, and an additional donor 10 were analyzed for the IFN gene analysis (shown in Fig. 9). Results presented in Figs. 446 were obtained from additional donors not represented in Figs. 1 and and22.

FIGURE 1.
ICs+C5b-9 triggers development of a CD4+IFN-γhigh population. A, flow cytometry analysis for IFN-γ production in naïve CD4+ T-cells on day 9 of post polarization with anti-CD3+ICs+C5b-9 and anti-CD3+anti-CD28. Treatment with anti-CD3+ICs+C5b-9 ...
FIGURE 2.
ICs+C5b-9 induces IL-17A expression. A, flow cytometry analysis for IL-17A production on day 9 of post polarization. Cells treated with anti-CD3+ICs+C5b-9 generated 7.67% IL-17A+ cells, and anti-CD3+anti-CD28 generated 3.12% IL-17A+ cells, shown in donor ...
FIGURE 4.
ICs+C5b-9 induces pathogenic TH17 cell genes. A, Rorc expression was increased upon ICs+C5b-9 co-stimulation in all five donors. In 2 of the 5 donors Rorc was increased from CD28 co-stimulation (n = 5). B, ICs+C5b-9 co-stimulation increased IL-6 (4.2-fold), ...
FIGURE 5.
Naïve CD4+ T-cells activated in vitro express CD25 and CD69, show pSyk, and produce IFN-γ. A, cells co-stimulated with either CD28 or ICs+C5b-9 express CD25 and CD69. B, ICs+C5b-9 co-stimulation triggered Syk phosphorylation. C, in vitro ...
FIGURE 6.
FcγRIIIa+CD4+ T-cells proliferate upon antibody and ICs ligation. FcγRIIIa+ T-cells show thymidine incorporation from plate-bound monoclonal anti-FcγRIIIa/b antibody (A), ICs (B), and anti-CD3+anti-CD28 (C). Both isotype control ...
FIGURE 9.
ICs+C5b-9 differentially expresses IFN pathway genes. PCR array analysis shows distinct and differential expression of IFN pathway genes in three donors. IFN pathway genes up-regulated from ICs+C5b-9 co-stimulation normalized over the level of gene transcripts ...

ICs and C5b-9

ICs were purified from 50 ml of pooled serum or plasma from 5–10 SLE patients that showed high levels of complement opsonized ICs. The purification procedures for ICs and C5b-9 have been previously described (11, 38, 39). The nature of the ICs used has been characterized for their binding to FcγRIII in multiple cell types, compared with AHG and anti-FcγRIIIa antibody (clone 3G8) (40). In addition the ICs were compared for their potential to activate CD4+ T-cells with in vitro formed Ova-anti-Ova ICs (11).

T-cell Culture and Differentiation

Peripheral blood mononuclear cells were isolated within 12 h of sample collection, and monocytes were removed by overnight plating in a culture dish. The next day the CD4+CD45RA+ cells were purified using naïve CD4+ T-cell isolation kit II (Miltenyi Biotec, Product no. 130-094-131). Purified cells were maintained in culture with 20 units of IL-2 for 2 days. Thereafter, these cells were stimulated with plate-bound ICs at 10 μg/ml and using purified soluble C5b-9 at 2.5 μg/ml for 1 × 106 cells in the presence of plate-bound anti-CD3 (eBioscience, clone OKT3) at 0.25 μg/ml. Positive control cells were stimulated with plate-bound 1 μg/ml anti-CD28 (clone 28.2) and 0.25 μg/ml anti-CD3. At 24 h post stimulation cells were cultured in the presence of IL-2 (20 IU), IL-1β (50 ng), IL-6 (50 ng), IL-23 (20 ng), and TGF-β1 (10 ng) for each ml of medium (Peprotech, Princeton, NJ). On days 9–11, cells were analyzed by flow cytometry for cytokine production. Cytokine levels were measured in the culture supernatants harvested on day five due to the concern for overgrowth in anti-CD3+anti-CD28 activation.

Thymidine Uptake

Naïve CD4+ T-cells were activated for 48 h with plate-bound anti-CD3+anti-CD28. Cells were then cultured in the presence of 20 units IL-2 and examined for binding of labeled ICs. Cells on day 7 were activated with plate-bound anti-FcγRIIIa/b (0.5 μg/ml), ICs (10 μg/ml), and anti-CD3+anti-CD28 (0.5 and 1 μg/ml). Thymidine uptake was measured using Click-iT Plus Edu Alexa-488 assay (Product no. C10632, Life Technologies) 96 h post activation. Cells alone and isotype control (0.5 μg/ml) were used as negative controls.

Flow Staining

Cell surface staining was done using antibody conjugated directly with fluorochromes at room temperature for 30 min as per the manufacturer's recommended use. The binding of labeled ICs was performed using 1 μg of protein label/106 cells for 30 min at room temperature. For intracellular cytokine staining, cells were stimulated with 1 μg/ml phorbol 12-myristate 13-acetate (PMA) and 2.5 μg/ml ionomycin for 4 h. Brefeldin at 5 μg/ml (Golgi Plus BD) was added after 1 h of PMA/ionomycin stimulation. Cells were collected for staining after 3 h. After cell surface staining the intracellular staining was performed using fixation/permeabilization reagents for IFN-γ, IL-17A, and IL-21 (eBioscience) according to manufacturer-suggested protocol. The following antibodies were used for cell surface or intracellular staining: Per-CP Cy5-anti-CD4, APC-anti-IFN-γ, PE-anti-IL21, PE-Cy7-anti-PD1, APC-eFluor780-anti-ICOS (eBioscience) PE-Cy7-anti-CD25, BV605-anti-CD69, BB515-anti-CD98, and Alexa Fluor 647-anti-IL-17A (BD Bioscience). PE-pSyk (Tyr-348) was purchased from eBioscience and PE-pSyk (Tyr-525/526) from Cell Signaling Technologies. Cells were stained in two panels: 1) anti-CD4, anti-pSyk (eBioscience), anti-IL-17A, anti-IFN-γ, and ICs; 2) anti-CD4, anti-CD25, anti-CD69, anti-CD98, and ICs. Staining using PE-pSyk (Cell Signaling Technologies) was performed in a separate panel from same samples. Stained cells were analyzed by flow cytometer (BD-LSRII, BD Biosciences). The flow data were analyzed with FlowJo software (Tree Star). CD4+-gated T-cells were analyzed for pSyk presence with CD25, CD69, CD98, ICs, IL-17A, and IFN-γ. The graphs were generated using GraphPad Prism 6. p values were calculated using non-parametric t test in Prism software.

Quantitative Real-time-PCR and PCR Array Analysis

Total RNA was prepared from cells harvested between days 4–5 post-stimulation using kit from Agilent Technologies (Wilmington, DE). Semiquantitative analysis for gene expression was carried from cDNA generated from total RNA using a high capacity cDNA kit (Applied Biosystems) using the comparative Ct (ΔΔCt) method. For Rorc (Hs01076122), endogenous control GAPDH (Hs02758991) (Applied Biosystems) was used. The RQ, RQ (minimum), and RQ (maximum) were calculated by StepOne software and plotted using GraphPad Prism. For gene expression cDNA was analyzed as per the manufacturer recommendation in the TaqMan Array for human IFN pathway (product no. 4418931) and analyzed in Data-assist. For calculating RQ, the corresponding genes in CD28 co-stimulated sample were used to normalize the expression. GAPDH, GUSB, and HPRT1 were used as endogenous controls for IFN array analysis. Analysis of variance was carried out using Partek Genomic Suite (Life Technologies). cDNA prepared from anti-CD3+anti-CD28 treated and anti-CD3+ICs+C5b-9-treated cells was analyzed for human Toll-Like Receptor Signaling Pathway genes using a RT2 Profiler PCR array plate (PAHS-018ZC, SAS Bioscience). Data were analyzed using vendor software, and ACTB, B2M, RPLP0, and GAPDH were used as endogenous controls included in the array.

Cytokine Measurement

Culture supernatants were collected from activated cells on day 5 and kept frozen at −70 °C. Cytokine measurements were performed using the multiplexing assay as per the manufacturer's instruction (EMD Millipore). For statistical analysis a non-parametric t test was performed using GraphPad Prism software.

Cell Staining

P116 cells (ATCC, CRL-2676), an acute T-cell leukemia ZAP-70 mutant was grown as per the guidelines from ATCC. These cells were activated as described in the previous section. Cells were harvested and washed with PBS and fixed in 4% formaldehyde for 15 min at room temperature. Cells were permeabilized using cold methanol at −20 °C for 10 min. Cells were then kept for 1 h in 1% BSA/PBS and stained using antigen-specific antibodies at a dilution of 1:100 in BSA/PBS for 1 h and developed using anti-species specific Alexa Fluor fluorochrome conjugate (Life Technologies) at appropriate dilutions. Anti-TLR antibodies were purchased from R&D Systems and eBiosciences. Anti-MyD88 and anti-HMGB1 was obtained from Cell Signaling Technologies. As a control for labeled ICs we used human IgG-conjugated with Alexa Fluor 488. Isotype controls for mouse monoclonal and purified rabbit IgG fraction were used as negative controls.

We stained human CD4+FcγRIII+ cells after treating them with plate-bound anti-CD3 (1 μg/ml) for 1 h with FITC-labeled anti-CD3 and anti-FcγRIIIa/b monoclonal (Clone245536) (R&D Systems). A secondary anti-mouse-Alexa-Fluor 594 was used to stain monoclonal anti-FcγRIIIa/b.

Results

ICs and C5b-9 Co-stimulation Generate CD4+IFNγhigh Population

IFN-γ is an autocrine TH1 differentiation factor that requires cytokine IL-12 for differentiation (19, 41). To examine whether ICs+C5b-9 contributes to CD4+ T-cell mediated pathological responses, we first examined the IFN-γ production in the presence of IL-1β, IL-6, IL-23, and TGF-β1 cytokines. Flow analysis showed substantial and reproducible increases in the IFN-γ producing populations on day nine post polarization (Fig. 1, A and B). We observed a high and moderate IFN-γ producing population (Figs. 1A and and22E). A statistically significant increase in IFN-γhigh population upon anti-CD3+ICs+C5b-9 treatment was observed compared with anti-CD3 treatment in 9 of 12 subjects analyzed (Fig. 1). These donors demonstrated an IFN-γhigh population upon ICs+C5b-9 co-stimulation (Fig. 1C). Donors 2, 7, and 9 also showed IFN-γ production in response to anti-CD3+anti-CD28 treatment. In nine donors that produced IFN-γ, combined analysis showed a statistically significant increase in IFN-γ producing population at a p value of 0.0026 in the anti-CD3+ICs+C5b-9-treated group compared with anti-CD3 group (Fig. 1D). In donor 7, a higher basal level of IFN-γ before activation was observed. This donor also showed elevated Tbx21 transcripts, suggesting an ongoing TH1 response at the time of sample collection (not shown).

The flow data were supported by an observed increase in IFN-γ levels in the culture supernatants post day five from the time of polarization. A statistically significant increase in IFN-γ production from anti-CD3+ICs+C5b-9 treatment, 14,398 ± 6,587 pg/ml (p value of < 0.0001), compared with untreated cells 1684 ± 338 pg/ml was observed (Fig. 3D). When compared with the anti-CD3-treated control group, anti-CD3+ICs+C5b-9-treated cells showed a statistically significant increase in IFN-γ at a p value of <0.0025. The positive control group treated with anti-CD3+anti-CD28 also showed an increase in IFN-γ production compared with untreated cells, 7571 ± 5887 versus 1684 ± 338 pg/ml, respectively, which was significant at a p value of <0.0001 (Fig. 3D). Untreated cells maintained in IL-2 (20 units/ml) showed minimal amounts of IFN-γ. These results confirm a role for ICs+C5b-9 for IFN-γ production in naïve CD4+ T-cells.

FIGURE 3.
ICs+C5b-9 triggers IFN-γ and TH17 cytokine production. IL-17A, IL-17F, IL-22, and IFN-γ measured in culture supernatants on day 5 post polarization. An increase in IL-17A was significant at p < 0.016 in anti-CD3+ICs+C5b-9 and <0.005 ...

ICs and C5b-9 Co-stimulation Generate a TH17-like Population

TH17 cells contribute to multiple autoimmune pathologies including SLE (28, 42). In humans, IL-17A production is driven by TGF-β (28, 43). Cytokines IL-1, IL-6, and IL-23 expand and stabilize this population (44). Flow analysis showed IL-17A producing cells upon ICs+C5b-9 co-stimulation in 9 of 12 subjects analyzed (Fig. 2, A and B). Donor 1 showed a minimal increase (Fig. 2C). The combined analysis showed a statistically significant increase at a p value of 0.016 from ICs+C5b-9 co-signal (Fig. 2D). Donors 3, 4, 5, 6, 8, and 9 showed a higher percentage of IL-17A+ cells from in vitro activation by anti-CD3+ICs+C5b-9. IL-17A-producing cells were also observed in donors 5, 7, and 8 in cells that received anti-CD3+anti-CD28 treatment. A higher percentage of IFN-γ- and IL-17A-producing populations were generated from ICs+C5b-9 co-stimulation. Proportionately, only a small fraction of cells were double positive for IFN-γ IL-17A cytokines (Fig. 2E).

Flow data were reconfirmed by the observed increases in the level of the cytokines IL-17A, IL-17F, and IL-22 in the culture supernatants, measured post day five from polarization. This time point was chosen to avoid differences arising from cell division in various activations. The amount of IL-17A produced in response to treatment with anti-CD3+ICs+C5b-9, compared with untreated cells, showed a statistically significant increase from 290 ± 169 to 2220 ± 1930 pg/ml (Mean ± S.E.) at a p value of <0.0169. The positive control group treated with anti-CD3+anti-CD28 also showed a significant increase, from 290 ± 169 to 1508 ± 955 pg/ml, a p value of 0.0055 (Fig. 3A). IL-17F also showed a statistically significant increase in the anti-CD3+ICs+C5b9-treated group compared with the untreated control, an increase from 579 ± 79 to 2979 ± 328 pg/ml with a p value of < 0.0001. A comparable increase was observed in the anti-CD3+anti-CD28-treated group, from 579 ± 79 to 2653 ± 2073 pg/ml, with a p value of <0.0001 (Fig. 3B). The addition of C5b-9 to the anti-CD3+ICs-treated group showed a statistically significant increase from 1937 ± 191 to 2978 ± 1042 pg/ml at a p value of 0.0035, suggesting a role for complement. There was no statistically significant difference in IL-17F production from co-stimulation with either CD28 or ICs+C5b-9. Although an increase in the IL-22 levels was observed in response to co-stimulation with CD28 as well as ICs+C5b-9, these values were not statistically significant (Fig. 3C). IL-22 production was also observed in flow analysis (not shown).

We also examined IL-21, a cytokine produced by both TH17 and TFH cells. IL-21 activates lymphocyte and regulates antigen specific antibody response (45, 46). All four donors examined showed enhanced production of IL-21 from ICs+C5b-9 co-stimulation. Donors 3 and 7 also showed IL-21 production from anti-CD3+anti-CD28 activation. The combined analysis of all four donors showed a statistically significant increase in the percentage of IL-21-producing cells upon ICs+C5b-9 co-stimulation (not shown).

ICs+C5b-9 Co-signal Triggers Expression of Genes Associated with TH17 Terminal Differentiation

We further confirmed the identity of TH17 cells by examining Rorc expression, a TH17 transcriptional regulator. All five donors analyzed showed a 2–8-fold increase in Rorc gene transcripts upon ICs+C5b-9 co-stimulation when normalized with transcript levels present in the anti-CD3-treated cells. Donors 4 and 5 were normalized using a control from another subject, as Rorc gene transcripts were not detectable in either untreated (not shown) or anti-CD3-treated cells used as negative controls (Fig. 4A). Csf2, IL-2, and Tbx21 are markers for the terminally differentiated pathogenic TH17 population (30). ICs+C5b-9 co-stimulation increased the expression of gene transcripts for IL-6, Csf2, IL-10, IL-12A, IL-1A, IL-1B, and IL-2 compared with the levels of transcript observed from CD28 co-stimulation (Fig. 4B, n = 3). The increase in the IL-6 transcripts was 4.21-fold and for Csf2 was 3.95-fold. These data suggest that the ICs+C5b-9 co-stimulation contributes to the development of the pathogenic TH17 population.

IC Engagement Phosphorylates Syk and Triggers Thymidine Uptake

To further confirm a role for FcγRIIIa-Syk signal in CD4+ T-cell activation, we examined the T-cell activation markers and pSyk upon in vitro activation of naïve CD4+ T-cells. Co-stimulation by CD28 or ICs+C5b-9 induced the expression of CD25 and CD69 (Fig. 5A). Co-stimulation by ICs+C5b-9 showed an increase in pSyk population (Fig. 5B). These pSyk+ cells expressed IFN-γ (Fig. 5C). IFN-γ production was observed in the absence of PMA and ionomycin treatment.

We further examined whether FcγRIIIa+CD4+ T-cells upon receptor ligation trigger thymidine uptake. Both anti-FcγRIIIa/b antibody (12.4%) and ICs (10.7%) ligation triggered thymidine uptake (Fig. 6). Cells activated with anti-CD3+anti-CD28 showed 18.6% cells in proliferation. Isotype antibody control (1.09%) and untreated cells (0.82%) did not show thymidine uptake. These results further confirm the presence of FcγRIIIa on CD4+ T-cells.

Confocal microscopic examination of z-series sections for CD3 complex and FcγRIIIa staining showed co-localization of these proteins (Fig. 6F). These results are in accordance with our previous observation and published report (11, 47).

CD4+pSyk+ T-cells in SLE Are an Activated Phenotype That Produces IFN-γ and IL-17A

To establish a role for Syk signaling in vivo, we next examined the presence of pSyk using two antibodies in the CD4+ T-cells within the peripheral blood mononuclear cells of SLE patients. Antibodies used recognized the Tyr-348 residue in Vav1 binding of human Syk and a second antibody that recognized the Tyr-525/526 residue in the kinase domain (Fig. 7A). Both of these antibodies confirmed the presence of pSyk in activated peripheral CD4+ T-cells that expressed CD25 (a and b), CD69 (c and d), and CD98 (e and f), all T-cell activation markers. We then examined the IC binding to CD4+ T-cells that expressed T-cell activation markers and pSyk (Fig. 7A, panels g, h, i, and j). Activated CD4+pSyk+ T-cells bound ICs, suggesting the presence of FcγRIIIa. These results suggest that in CD4+ SLE T-cells, Syk signaling contributes to cell activation (11, 48). Activated CD4+ T-cells express FcγRIIIa (40). The presence of pSyk in activated CD4+ T-cells in the patient population is also supported by our previous studies where we showed Syk phosphorylation during T-cell activation (38). A role for Syk in the development of TH1 and TH17 responses via dendritic cell activation has been also been suggested (49).

FIGURE 7.FIGURE 7.
CD4+ T-cells show pSyk and produce IFN-γ and IL-17A. A, CD4+ T-cells in patients' peripheral blood mononuclear cells show pSyk, and express CD25, CD69, and CD98; in panels a, c, and e antibody recognizes the Tyr-348 residue, and in panels b, ...

We next examined whether the activated pSyk+CD4+ T-cells in SLE patients produced IFN-γ and IL-17A. Flow analysis showed that the pSyk+ cells both at Tyr-348 or Tyr-525/526 produced IFN-γ and IL-17A (Fig. 7B). Data from two patients show 7.77 and 9.31% pSyk+IFN-γ+ cells in donor 1 (panels a and b) and 4.48 and 4.82% in donor 2 (panels e and f), respectively. Donor 1 showed 7.10% and 7.82% of pSyk+IL-17A+cells (panels c and d) and 3.32% and 3.38% population in donor 2 (panels g and h). A minor population of IL-17Ahigh was also observed in several subjects. These cells were analyzed without activation by PMA, ionomycin, and brefeldin A treatment. Analysis of 29 patients showed that pSyk+ cells were activated CD4+ T-cells, which produced IFN-γ and IL-17A cytokines. Individual and combined analysis of these 29 subjects as a group demonstrated that the percentage of pSyk+FcγRIIIa+ (IC binding cells); pSyk+CD25+, pSyk+CD69+, and pSyk+CD98+ cells did not vary significantly (Fig. 7C). These results suggest that the activated CD4+ T-cells signal via Syk and produce inflammatory cytokines. To further confirm the role for Syk signaling, we gated CD4+ T-cells for pSyk+ and IC binding (double positive) and examined this population for IFN-γ and IL-17A production. This analysis showed two subsets of IFN-γ-producing cells, IFN-γmoderate and IFN-γhigh (Fig. 7D). Analysis of these IFN-γ subsets showed various levels of IL-17A-producing cells; IFN-γhigh always showed a higher percentage of IL-17A+ cells, 14.2%, 29.2%, and 12.9%, compared with 8.94%, 1.31%, and 1.38% in IFN-γmoderate cells (Fig. 7D). These results concur with results obtained from in vitro co-stimulation of naive CD4+ T-cells suggesting a role for an ICs+C5b-9-mediated signal.

We also examined IFN-γ production in P116 cells, a ZAP-70 mutant of Jurkat cells that can only signal via Syk (17). Again, co-stimulation from ICs+C5b-9 in P116 cells produced IFN-γ+ cells (not shown).

ICOS+ but Not PD1high Cells Show pSyk in SLE-CD4+ T- cells

ICOS and PD1 are key membrane regulators of CD4+ T-cell response. Thus we next examined whether pSyk+FcγRIIIa+ cells express these proteins. In all 15 donors analyzed, ICOS+ CD4+ T-cells also showed pSyk (Fig. 8A). Cells that expressed ICOS bound to ICs (Fig. 8B). However, those cells that expressed high levels of PD1 (PD1high) lacked pSyk. pSyk+ cells expressed low levels of PD1 (Fig. 8, panels C and D). A higher percentage of PD1high cells with high mean fluorescence intensity values was observed compared with PD1lowpSyk+ cells (Fig. 8H). In only two patients the mean fluorescence intensity for PD1 was equal or slightly higher in cells with pSyk. A role for PD1 in down-regulation of Syk phosphorylation via SHP2 has been shown (50). PD1high cells did not bind to ICs, although in some patients both moderate PD1 levels and an IC binding population was observed (Fig. 8 panels E and F). A paired t test showed a statistically significant correlation among pSyk and ICOS expression at a p value of <0.0001, with a strong correlation (r = 0.77). However, a correlation between pSyk and PD1 expression was not observed (r = 0.22) (Fig. 8, panel G). It is likely that PD1 dephosphorylated Syk via SHP2. These data suggest a possible role for FcγRIIIa-Syk signaling in modulating responses of CD4+ T-cell membrane regulators (Fig. 8).

FIGURE 8.
pSyk+CD4+ T-cells express ICOS and not PD1. pSyk+CD4+ T-cells express ICOS (A) and bind to ICs (B). PD1high cells do not show pSyk and IC binding. Cells with low PD1 expression show pSyk (showing 2 of 15 analyzed, C and D). PD1high cells do not bind to ...

ICs+C5b-9 Provides a Distinct Co-stimulatory Signal for IFN-pathway Gene Expression

IFN inducible gene “signature” serves as a marker of lupus nephritis (25). We analyzed expression of IFN signaling pathway genes from ICs+C5b-9 co-stimulation and compared it with the CD28 co-signal. Three donors, 8, 9, and 10, showed strong expression of IFN pathway genes, which were differentially expressed from two co-stimulations (Fig. 9). Interestingly, donor 8 showed expression of type I IFN genes, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, and IFNW, which were further up-regulated after ICs+C5b-9 co-stimulation (Fig. 9, blue bars donor 8). The IFNA1, -2, -4, -5, -6, -7, -8, -14, and -17 were up-regulated over 6-fold with only a 1.53- and 1.26-fold increase in IFNAR1 and IFNAR2, respectively. These receptors are utilized by type I IFNs. Donor 9 showed increased expression of type II IFN responses (Fig. 9, red bars). MAP2, MAP3, and PIK3 kinases showed a >5-fold increase in donors 9 and 10 (Fig. 9). In donor 8, insulin receptor substrate 2 (IRS2) showed a 20-fold increase. IRS2 along with IRS1 acts as an adaptor substrate for the type I IFN signaling. IRS2 is negatively regulated by the cyclic AMP response element-binding protein 3-like 4 (CREB3L4), which was shut down by ICs+C5b-9 co-stimulation (Fig. 9). Donor 9 with a long history of SLE and nephritis showed an 87-fold increase in IFN-γ expression and downstream signaling genes (Fig. 9, donor 9 red bars). Other notable increases were observed in expression of JAK1, JAK2, IRF-9, TYK2, STAT1, and STAT2. Donor 10 (Fig. 9, green bars) also showed an increase in the expression of IFN-β1. Pronounced expression of PI3K in response to ICs+C5b-9 co-stimulation was observed. These results suggest a distinct up-regulation of IFN genes in each donor from ICs+C5b-9 stimulation.

ICs+C5b-9 Up-regulate TLR Signaling Pathway Genes

TLRs play a role in adaptive immune responses (35). To examine whether TLR signaling synergizes the FcγRIIIa-Syk-mediated signal in modulating T-cell responses, we analyzed the expression of TLR signaling genes. We analyzed naïve CD4+ T-cells from five paired samples under identical culture conditions. Cells were co-stimulated with ICs+C5b-9, and the gene expression levels were compared with cells co-stimulated using ani-CD28 from the same subject. Combined analysis of five samples showed increased expression of TLR-interacting proteins and adaptors such as Bruton agammaglobulinemia tyrosine kinase (Btk) (2.92), HMGB1 (3.62), Harvey ras sarcoma virus oncogene homolog (HRAS) (4.91), and MyD88 (2.34). Myd88-dependent signaling TLRs, TLR2 (5.50), TLR4 (2.23), TLR5 (5.17), TLR7 (2.55), and TLR10 (5.16), showed significant increases, whereas TLR9 (1.03) did not show any increase. TIRAP (5.21), which is essential for TLR2 and TLR4 signaling, was up-regulated. Expression of TRAF6 (4.65), a TNF receptor-associated family factor, is an E3 ubiquitin ligase that signals via the Toll/IL-1 family, which was also increased. Proteins that influence the adaptive responses, TRAF6 (4.65), IL10 (2.99), IL12B (2.31), IL1A (3.05), and IL1B (2.68), showed increased expression (Fig. 10). TLR3 (9.89), a MyD88-independent signal, showed the highest increase in the gene expression (Fig. 10). Two donors, 8 and 12, showed the maximum up-regulation of TLRs (Fig. 10B). In these two donors we compared the up-regulation of TLR signaling genes from untreated cells with CD28 and ICs+C5b-9 co-stimulation. IL-12A was significantly up-regulated by both co-signals. Cells activated with the ICs+C5b-9 co-signal showed a significant increase in many genes, notably HMGB1 (20.66), IL-1B (11.25), IL-10 (10.71), TLR3 (88.22), TLR7 (13.16), TLR8 (80.49), TLR9 (17.59), TLR10 (19.17), and TRAF6 (20.74) (Fig. 10 and Table 1). TLR3 showed the most increase and is shown to aggravate lupus nephritis (51). To examine the presence of TLR proteins and their association with FcγRIIIa in CD4+ T-cells, we stained P116 cells after co-stimulation with ICs+C5b-9. ICs co-localized with MyD88 (supplemental Movie 1), HMGB1 (supplemental Movie 2), TLR3 (supplemental Movie 3), TLR5 (supplemental Movie 4), and TLR9 (supplemental Movies 5 and 6), MyD88, and HMGB1 along with IC localized on the cell membrane (Fig. 11). TLR3 and TLR9 colocalized with ICs on membrane (Fig. 11A, panels e and f and panels k and l; supplemental Movies 3 and 6). Both of these proteins were also present in the endolysosome. This was confirmed using LysoTracker deep red (Molecular Probes). These proteins appear in microclusters. IC binding showed a pattern of receptor capping. Even though we did not see up-regulation of TLR9 transcripts upon ICs+C5b-9 co-stimulation at the protein level in naïve CD4+ T-cells, we observed the TLR9 protein in P116 cells and activated human CD4+ T-cells. We observed two staining patterns for TLR9. The first pattern was with membrane staining and intracellular staining for ICs (Fig. 11A, panels i and j). In the second staining pattern ICs showed membrane staining and TLR9 in endolysosomes forming a ball-like structure (Fig. 11A, panels k and l, supplement Movie 5). TLR9 co-stained with ICs, suggesting their co-localization. Untreated P116 cells showed mostly membrane staining for ICs and TLR9. A similar staining pattern was also observed for TLR3. In Western blot analysis, both HMGB1 and MyD88 were observed in immunoprecipitates prepared using anti-CD16 (clone 3G8) antibody (data not shown). These data suggest a role for FcγRIII-Syk signaling in the up-regulation of TLR signaling pathways in CD4+ T-cells.

FIGURE 10.
ICs+C5b-9 up-regulates TLR signaling genes. A, ICs+C5b-9 co-stimulation of naïve CD4+ T-cells induced expression of TLR genes severalfold. Both MyD88-dependent and independent genes as well as adaptors show enhanced gene expression (n = 5). B ...
TABLE 1
Expression of TLR pathway genes from two co-stimulations
FIGURE 11.
Co-localization of TLR pathway proteins with FcγRIIIa. A, P116 cells stained for IC binding and TLR pathway proteins. MyD88 (a and b), HMGB1 (c and d), TLR3 (e and f), TLR5 (g and h), and TLR 9 co-localized with IC binding (green) (i, j, k, and ...

Our results thus suggest that FcγRIIIa-pSyk is a distinct co-signal in CD4+ T-cells that drives the differentiation of naïve cells into IFN-γhigh and IL-17A+ populations. FcγRIIIa-pSyk signal up-regulated the genes associated with terminal differentiation of pathogenic TH17 cells. FcγRIIIa-pSyk is a distinct and potent signal for up-regulation of the IFN signaling pathway. The FcγRIIIa-pSyk population is present in SLE patients. The ligation of FcγRIIIa by ICs up-regulated the TLR signaling pathway genes. These data suggest a possible synergistic role of TLR and FcγRIIIa signaling in human CD4+ T-cells.

Discussion

In this report we show that the ICs+C5b-9 acts as a co-stimulator of naïve CD4+ T-cells. ICs+C5b-9 generates a co-stimulatory signal that is mediated via FcγRIIIa-Syk phosphorylation. This ICs+C5b-9-mediated signal efficiently replaced the CD28 requirement for the development of CD4+IFN-γ+high and a TH17 like population. The FcγRIIIa-pSyk is a distinct co-signal from CD28, as it differentially expressed IFN genes and up-regulated TLR signaling pathways genes. Naïve CD4+ T-cell activation, survival, subset differentiation, and effector function are regulated by the co-signaling proteins present on CD4+ T-cell membrane (52). A co-stimulatory signal from CD28 (signal 2 of two signal hypothesis) is a key requirement for naïve CD4+ T-cell activation without which cells become anergic. In an autoimmune background, CD4+ T-cells bypass the need of CD28 co-signal to become fully activated (10). However, the mechanism underlying this activation is unknown. Our results suggest that in an autoimmune response, FcγRIIIa-Syk signal is important for the activation of naïve CD4+ T-cells. In CD4+ T-cells that express FcγRIIIa, ICs ligation triggers FcRγ chain phosphorylation, which then co-localizes and signal via Syk (38, 53). Although C5b-9 is essential to trigger MR clustering, ICs engage FcγRIIIa and trigger Syk activation (11). Both ICs and C5b-9 are required for phosphorylation of TCR signaling proteins and triggering of T-cell activation-associated changes (11). Co-localization of ICs with in situ assembled C5b-9 and CD3 complex suggests a cooperative response among these complexes (11). On CD4+ T-cell membrane ICs binding occurred at the site of FcγRIIIa staining, confirming the presence of these receptors (40). FcγRIIIa colocalize with the CD3 complex on the cell membrane (Fig. 6F). Previous studies have also shown colocalization of FcR with TCR on activated T-cells (47). In SLE-CD4+ T-cells, the FcRγ chain associates with the CD3 ζ-chain of TCR and signals via Syk (53). Rewiring of TCR-CD3 complex, where the CD3-ζ chain is replaced by the FcRγ chain, which signal via Syk in SLE T-cells is shown (16). Up-regulation of both the FcRγ chain and Syk is observed in TE cells, unlike naïve cells (16). The T-cell activation via CD28 signaling upon TCR engagement in the absence of ZAP-70 signaling can utilize Syk. The engagement of FcγRIIIa can only generate the Syk-mediated signal. In the presence of IL-2 and IL-12, ICs+C5b-9 co-signals with suboptimal CD3 ligation generated a TH1-like population (40). Intravenous gamma globulin therapy, which works by blocking low affinity FcRs, reciprocally regulates human pathogenic TH1, TH17, and Treg cells (54). Based on our results and the existing literature, we propose that the low affinity FcγRIIIa-mediated phosphorylation of Syk is an important signal for the development of proinflammatory CD4+ TE cells (17, 48). Additionally, TLR signal up-regulation from FcγRIIIa ligation by ICs may result in the development of proinflammatory cells that may be refractory to suppression by Tregs. A role for IL-1, IL-6, and LPS signal that utilizes MyD88 an adaptor for Toll/IL-1 receptor is implicated in overcoming the suppression by Tregs (55,57). Cooperation among FcγR-TLR signaling in M1 and M2 macrophages activates Syk kinase, which then produces proinflammatory cytokines (58). An association of TLR4 with FcγRIII upon ICs stimulation of mouse macrophages is observed (59). A similar cooperation between FcγRIIIa and TLR signals in CD4+ T-cells could modulate adaptive immune responses in humans.

The expression of co-stimulatory proteins on naïve CD4+ T-cells is limited, and CD28 is the only primary protein known to prime these cells (60). ICs+C5b-9 successfully primed human peripheral naïve CD4+ T-cells in the absence of CD28 co-signal. The co-signal generated by ICs+C5b-9 was efficient and potent enough to support the development of IFN-γhigh and IL17A+-producing cells, which only required IL-1β, IL-6, IL-23, and TGF-β1, without IL-4 and IFN-γ suppression (Figs. 1 and and2).2). For differentiation of mouse naïve CD4+ T-cells into TH17 cells, IFN-γ and IL-4 suppression is required. We did not observe this requirement.

Altered CD4+ T-cell responses are a common feature of autoimmune pathology, which is often accompanied by elevated IC levels and complement activation byproducts such as C5b-9 (61, 62). The elevated serum and urine levels of C5b-9 are associated with disease activity. In our model the C5b-9 contributes to cell activation by lateral clustering of MRs, which brings the receptors and signaling proteins to close proximity (11). MRs are uniformly distributed on T-cells from healthy individual and are aggregated and clustered in SLE T-cells (63). MRs aggregation is observed in the mouse model of SLE (64). Atorvastatin reversed MR signaling abnormalities in SLE T-cells (65). FcγR engagement by ICs in many cell types drive IFN production (66). The CD4+FcγRIIIa+IFN-γhigh cells generated via FcγRIIIa-pSyk signaling represent a new subset of T-cells. Co-expression of TLR proteins in these cells could render them refractory to Treg suppression (55).

ICs are often present in the immune deposits along with C5b-9 proteins. Recent studies have also shown that ICs are held without phagolysis by subcapsular sinus macrophages, B cells, and follicular dendritic cells on the cell membrane (67, 68). The retention and passive exchange of intact ICs occur among several cell types within the germinal centers. Follicular dendritic cells recycle the ICs, which make them accessible to antigen-specific B cells (68). In many disease tissues the formation of ectopic germinal centers are often observed. At these sites and in systemic circulation, ICs can drive differentiation of naïve CD4+ T-cells and produce IFN-γ, IL-17A, and IL-21, which can augment antigen-specific antibody responses (45).

During TH1 response, IFN-γ is produced in two waves, and the secondary IFN-γ production is driven by an autocrine IFN-γ signal (41). Two populations of IFN-γ-producing cells in SLE CD4+ T-cells IFN-γmoderate and IFN-γ+high were observed both in vivo and upon in vitro activation (Figs. 1, ,2,2, and and7).7). The IFN-γmoderate population likely represents the bystander secondary T-cell response (Fig. 2E). In an in vitro experiment, a secondary short term challenge by ICs produced IFN-γmoderate cells, which was accompanied by a proportionate loss of IC binding (not shown). We examined cytokines in the SLE T-cells without PMA and ionomycin activation to avoid the influence of these potent T-cell activators. Our in vitro data on cytokine production and ICs binding was supported by the in vivo presence of such cells in SLE patients. Those SLE CD4+ T-cells that expressed the T-cell activation markers, CD25, CD69, and CD98, also showed pSyk, bound to labeled ICs, and produced cytokines, suggesting a role for Syk signaling (Fig. 7A). A role for anti-CD3 antibodies in rewiring of the CD3 complex with Syk has been suggested in SLE T-cells (48). However, the presence of anti-CD3 antibodies in SLE pathology has not been documented. In our experiments, anti-CD3-treated cells alone did not generate IFN-γ or IL-17A-producing populations. Therefore, we propose that this Syk rewiring of the TCR complex occurred from IC ligation of FcγRIIIa. Labeled ICs co-localize with CD3 complex in activated CD4+ T-cells, suggesting the presence of FcγRIIIa (11). ICOS-expressing cells showed pSyk, implying the co-presence of these proteins in activated T-cells. pSyk+ cells showed low levels of PD1 expression. Cells expressing high levels of PD1 did not show pSyk. PD1 is an inhibitory co-stimulating signal that acts by recruiting phosphatase SHP2. ZAP-70-deficient patients show abnormal peripheral CD4+ T-cells and express high levels of Syk, which drives T-cell activation (17). Kinase activity of Syk is 100-fold higher than that of ZAP-70, and Syk demonstrates a differential intrinsic activity compared with ZAP-70 (69). Syk is essential for innate responses and is a key signaling protein in B-cells (70). Further support for the role of Syk in CD4+ T-cell differentiation also comes from production of IFN-γ by P116 cells upon co-stimulation with ICs+C5b-9. These cells express FcγRIIIa upon activation (40). We speculate that the FcγRIIIa-pSyk-mediated IFN-γ production observed upon IC ligation is driven by the occupancy of the −53 CpG site in the IFN-γ promoter by ATF2 (71). A 5.3-fold increase in ATF2 (n = 5) was observed upon IC+C5b-9 co-stimulation normalized to the level of transcripts observed from CD28 co-stimulation (Fig. 9A). ATF2 also activates IL-23p19 promoter and has three binding sites in the IL-17 promoter.

A strong association of IL-17A and other TH17 cytokines in SLE pathogenesis in mouse model has been reported (20, 72). IL-23 cytokine, which is elevated in SLE patient sera, contributes to the terminal differentiation of pathogenic TH17 cells. ICs+C5b-9 co-stimulation induced overexpression of Csf2, IL-6, and IL-2 associated with the pathogenic TH17 cell population (Fig. 4B) (30). Additionally, IL-10, IL-12A, IL-1α, and IL-1β transcripts were up-regulated (Fig. 4B).

IFNs are critical in RA and SLE pathogenesis (25, 73, 74). DNA- and RNA-containing ICs trigger IFN-α production from plasmacytoid dendritic cells by engaging FcγRIIa with TLR7 and TLR9 (34, 75). We observed the expression of all 13 type I IFN genes, which were up-regulated by ICs+C5b-9 co-stimulation in one donor (Fig. 9, blue bars). This donor also showed a 20-fold increase in IRS2. Both IRS1 and IRS2 act as an adaptor for type I IFN-mediated signaling events. IRS2 is negatively regulated by cAMP response element-binding protein 3-like 4 (CREB3L4). A genetic interaction of the CREB, a co-activator with IL-12/STAT4 protein during TH1 differentiation, prolongs IFN-γ synthesis (76). We are not aware of any previous report of type I IFN expression in human CD4+ T-cells. IFN pathway gene array analysis showed a unique gene signature up-regulation in all three subjects analyzed (Fig. 9). The IFN gene expression profile suggests the ICs+C5b-9 co-signal differentially up-regulated expression of IFN pathway genes, suggesting a bifurcation of signaling events.

An individual role for TLRs and FcRs in inflammatory responses has been documented. Interplay between the members of these two receptor families has started to emerge in inflammatory diseases. Simultaneous engagement of TLRs and FcRs on dendritic cells is essential for production of IL-1β and IL-23 (77). A cross-talk between TLRs and FcRs initiated by ICs and pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) in autoimmune diseases is now proposed (77). Human CD4+ T-cells and Jurkat cells express RNA that encodes most of TLRs (78). TLRs play a role in T-cell activation and differentiation during autoimmunity (35, 78). TLRs also modulate CD4+ T-cell response (79, 80). In human naïve CD4+ T-cells, ICs+C5b-9 co-stimulation up-regulated TLR2, -3, -5, -8, -10, HMGB1, and MyD88 gene transcripts (Fig. 10). This suggests that the activation of CD4+ T-cells by ICs+C5b-9 sensitize them for danger signals. The TLR5 ligand, flagellin in the presence of suboptimal anti-CD3 ligation and in the absence of APC triggers cell proliferation, as well produces IFN-γ and IL-8 (81). Chromatin-IgG complexes activate B-cells by dual engagement of B-cell receptor and TLR (82). Such synergism between TCR and FcRs with TLRs in CD4+ T-cells has not been shown but could occur in human FcγRIIIa+CD4+ T-cells. FcγRIIIa-TLR engagement will have a wide-ranging implication in autoimmunity. DNA-ICs ligate FcγRIIa in plasmacytoid dendritic cells and up-regulate TLR9, which then drive the IFN response in SLE. Our results suggest that in CD4+ T-cells FcγRIIIa could co-operate with TLRs to drive proliferation and IFN production (11, 40). TLR adaptor molecule-1 (TICAM1), which interacts with TLR3 and other MyD88-dependent TLRs, were up-regulated. In response to double-stranded RNA viruses, TLR3 produces IFN-β via IRF3. Poly I:C, a TLR3 ligand, activates human CD4+ T-cells (83). In the same study the TLR5 expression was also observed on CD4+ T-cells, but the activation with flagellin was not sufficient to activate these cells. Even though TLR responses in the CD4+ cells has been documented, the receptor by which the nucleic acids are delivered to endolysosomes is unknown. Our result suggests a possible role of FcγRIIIa in delivering DNA-ICs to endolysosomes in activated CD4+ T-cells where they could interact with TLR9 (Fig. 11). DNA- or RNA-containing ICs via HMGB1 can efficiently deliver self nucleic acid to TLR containing endolysosomes (84). HMGB1 is a DNA chaperon that is capable of organizing dynamic active chromatin structures. It is diffusely distributed in cytoplasm and is released from inflamed cells actively or from apoptotic and necrotic cells. Elevated serum levels of HMGB1 are observed in SLE patients during flares. HMGB1 has a proinflammatory effect, which is mediated via TLR2, -4, and -9 (78). ICs+C5b-9 co-signal up-regulated HMGB1 gene transcripts in naïve CD4+ T-cells and the HMGB1 protein co-localized with ICs in human CD4+ T-cells and P116 cells. Ablation of MyD88 in CD4+ T-cells impairs both TH1 and TH17 responses (56). We observed the overexpression of MyD88 transcripts and MyD88 protein co-localized with ICs. Both HMGB1 and MyD88 proteins were observed in co-immunoprecipitates obtained using anti-FcγRIIIa/b antibodies from P116 cells.3 A role for MyD88 in proliferation and IFN-γ production in mice infected with Ehrlichia muris has been observed (85). TLR9 agonist in CD4+ T-cells enhanced proliferation, survival, and IL-2 secretion (79). Subcellular localization of TLR9 using HEK293T cells has been shown to be critical in discriminating self versus non-self DNA (37). TLR9 reside in endoplasmic reticulum, and upon stimulation from CpG DNA it is recruited to lysosomes (86). Upon ICs+C5b-9 co-stimulation in P116 cells TLR9 protein localized in endolysosomes with ICs. This pattern was confirmed in human CD4+ T-cells. We also observed membrane staining for TLR9 with cytoplasmic IC binding. This suggests a possible role for FcγRIIIa in recruiting TLR9 to endo lysosomes. The significance of these events in the development of autoimmune response remains to be determined. Our results suggest a critical role for FcγRIIIa-pSyk signal in CD4+ T-cell-mediated adaptive immunity.

In summary, our results establish a co-stimulatory role for ICs+C5b-9 in the development of the CD4+IFN-γhigh cell subset and a TH17 like population. ICs+C5b-9 provides a distinct co-stimulatory signal for the up-regulation of the IFN and TLR signaling pathway genes. The data provide a link for ICs in driving TLR-dependent T-cell activation in autoimmunity (35). T-cell signaling responses by TLRs result in tolerance breakdown and bystander activation of auto reactive TH1 and TH17 cells. An abnormal activating co-stimulatory signal from ICs+C5b-9 during immune contraction can override the inhibition by CTLA-4 and PD1, resulting in peripheral tolerance breakdown. A further understanding of ICs+C5b-9 signaling in CD4+ T-cells will lead to a better understanding of the role of CD4+ T-cells in diseases like SLE. These findings will not only be relevant to autoimmune disorders but also in cardiovascular diseases, cancers, and viral infections. Both PD1 and CTLA-4 proteins are therapeutic targets. A role for activating FcRs is also suggested in the therapies targeting CTLA-4. It is important to further explore the role of FcγRIIIa signaling in CD4+ T-cells.

Author Contributions

A. K. C. designed research, performed experiments, analyzed and interpreted results, and wrote the manuscript. T. L. M. obtained clinical material, clinical information, and reviewed the manuscript. C. C. and Y. B. performed the experiments.

Supplementary Material

Supplemental Data:

Acknowledgments

We thank Drs. Eline T. Luning Prak (University of Pennsylvania) and Andy Chan (Genentech) for critical reviews of this work. We thank Xiaowen Wang of Partek Genomics for assistance with PCR array data analysis.

*This work was supported by National Institutes of Health RO1 Grant A1098114 (to A. K. C.). The authors declare that they have no conflict of interest with the content of this article.

An external file that holds a picture, illustration, etc.
Object name is sbox.jpgThis article contains supplemental Movies 1–6.

3A. K. Chauhan, unpublished observation.

2The abbreviations used are:

IC
immune complex
SLE
systemic lupus erythematosus
MR
membrane raft
TCR
T-cell receptor
RA
rheumatoid arthritis
TLR
Toll-like receptor
pSyk
phosphorylate Syk
PMA
phorbol 12-myristate 13-acetate
Csf
colony stimulating factor
IRS2
insulin receptor substrate 2
FcR
Fc-receptor
APC
allophycocyanin
PE
phycoerythrin
ICOS
inducible co-stimulator
RQ
realtive quantitation.

References

1. Miura Y. (1989) Studies on circulating immune complexes. III: Kinetics of the immunoglobulin class of circulating immune complexes in systemic lupus erythematosus. Nihon Jinzo Gakkai shi 31, 201–209 [PubMed]
2. Chiu Y. Y., Nisihara R. M., Würzner R., Kirschfink M., and de Messias-Reason I. J. (1998) SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J. Investig. Allergol. Clin. Immunol. 8, 239–244 [PubMed]
3. Davies K. A., Robson M. G., Peters A. M., Norsworthy P., Nash J. T., and Walport M. J. (2002) Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum. 46, 1028–1038 [PubMed]
4. Vinuesa C. G., Sanz I., and Cook M. C. (2009) Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9, 845–857 [PubMed]
5. Engelhardt W., Matzke J., and Schmidt R. E. (1995) Activation-dependent expression of low affinity IgG receptors FcγRII(CD32) and FcγRIII(CD16) in subpopulations of human T lymphocytes. Immunobiology 192, 297–320 [PubMed]
6. Sandor M., Galon J., Takacs L., Tatsumi Y., Mueller A. L., Sautes C., and Lynch R. G. (1994) An alternative Fc γ-receptor ligand: potential role in T-cell development. Proc. Natl. Acad. Sci. U.S.A. 91, 12857–12861 [PubMed]
7. Agarwal A., and Newell K. A. (2008) The role of positive costimulatory molecules in transplantation and tolerance. Curr. Opin. Organ Transplant. 13, 366–372 [PubMed]
8. Greenwald R. J., Freeman G. J., and Sharpe A. H. (2005) The B7 family revisited. Annu. Rev. Immunol. 23, 515–548 [PubMed]
9. Zhu Y., Yao S., and Chen L. (2011) Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34, 466–478 [PMC free article] [PubMed]
10. Bour-Jordan H., Esensten J. H., Martinez-Llordella M., Penaranda C., Stumpf M., and Bluestone J. A. (2011) Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol. Rev. 241, 180–205 [PMC free article] [PubMed]
11. Chauhan A. K., and Moore T. L. (2011) T-cell activation by terminal complex of complement and immune complexes. J. Biol. Chem. 286, 38627–38637 [PMC free article] [PubMed]
12. Hori S. (2011) Regulatory T-cell plasticity: beyond the controversies. Trends Immunol. 32, 295–300 [PubMed]
13. Lee Y. K., Turner H., Maynard C. L., Oliver J. R., Chen D., Elson C. O., and Weaver C. T. (2009) Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92–107 [PMC free article] [PubMed]
14. Nistala K., Adams S., Cambrook H., Ursu S., Olivito B., de Jager W., Evans J. G., Cimaz R., Bajaj-Elliott M., and Wedderburn L. R. (2010) Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl. Acad. Sci. U.S.A. 107, 14751–14756 [PubMed]
15. O'Shea J. J., and Paul W. E. (2010) Mechanisms underlying lineage commitment and plasticity of helper CD4+ T-cells. Science 327, 1098–1102 [PMC free article] [PubMed]
16. Krishnan S., Warke V. G., Nambiar M. P., Tsokos G. C., and Farber D. L. (2003) The FcR γ subunit and Syk kinase replace the CD3 ζ-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T-cells. J. Immunol. 170, 4189–4195 [PubMed]
17. Noraz N., Schwarz K., Steinberg M., Dardalhon V., Rebouissou C., Hipskind R., Friedrich W., Yssel H., Bacon K., and Taylor N. (2000) Alternative antigen receptor (TCR) signaling in T-cells derived from ZAP-70-deficient patients expressing high levels of Syk. J. Biol. Chem. 275, 15832–15838 [PubMed]
18. Grammatikos A. P., Ghosh D., Devlin A., Kyttaris V. C., and Tsokos G. C. (2013) Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T-cell signaling. PLoS ONE 8, e74550. [PMC free article] [PubMed]
19. Hu X., and Ivashkiv L. B. (2009) Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases. Immunity 31, 539–550 [PMC free article] [PubMed]
20. Martin J. C., Baeten D. L., and Josien R. (2014) Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin. Immunol. 154, 1–12 [PubMed]
21. Lazarevic V., and Glimcher L. H. (2011) T-bet in disease. Nat. Immunol. 12, 597–606 [PubMed]
22. Schroder K., Hertzog P. J., Ravasi T., and Hume D. A. (2004) Interferon-γ: an overview of signals, mechanisms, and functions. J. Leukoc. Biol. 75, 163–189 [PubMed]
23. Qiao Y., Giannopoulou E. G., Chan C. H., Park S. H., Gong S., Chen J., Hu X., Elemento O., and Ivashkiv L. B. (2013) Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. Immunity 39, 454–469 [PMC free article] [PubMed]
24. Lee S. K., Silva D. G., Martin J. L., Pratama A., Hu X., Chang P. P., Walters G., and Vinuesa C. G. (2012) Interferon-γ excess leads to pathogenic accumulation of follicular helper T-cells and germinal centers. Immunity 37, 880–892 [PubMed]
25. Baechler E. C., Batliwalla F. M., Karypis G., Gaffney P. M., Ortmann W. A., Espe K. J., Shark K. B., Grande W. J., Hughes K. M., Kapur V., Gregersen P. K., and Behrens T. W. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U.S.A. 100, 2610–2615 [PubMed]
26. Gordon R. A., Grigoriev G., Lee A., Kalliolias G. D., and Ivashkiv L. B. (2012) The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment. Arthritis Rheum. 64, 3119–3128 [PMC free article] [PubMed]
27. Higgs B. W., Liu Z., White B., Zhu W., White W. I., Morehouse C., Brohawn P., Kiener P. A., Richman L., Fiorentino D., Greenberg S. A., Jallal B., and Yao Y. (2011) Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70, 2029–2036 [PubMed]
28. Bettelli E., Oukka M., and Kuchroo V. K. (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345–350 [PubMed]
29. Pisitkun P., Ha H. L., Wang H., Claudio E., Tivy C. C., Zhou H., Mayadas T. N., Illei G. G., and Siebenlist U. (2012) Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity 37, 1104–1115 [PMC free article] [PubMed]
30. Gaffen S. L., Jain R., Garg A. V., and Cua D. J. (2014) The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585–600 [PMC free article] [PubMed]
31. Chugh P. K. (2012) Lupus: novel therapies in clinical development. Eur. J. Intern. Med. 23, 212–218 [PubMed]
32. Crow M. K. (2010) Interferon-α: a therapeutic target in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 36, 173–186 [PMC free article] [PubMed]
33. Hueber W., Patel D. D., Dryja T., Wright A. M., Koroleva I., Bruin G., Antoni C., Draelos Z., Gold M. H., Psoriasis Study Group, Durez P., Tak P. P., Gomez-Reino J. J., Rheumatoid Arthritis Study Group., Foster C. S., Kim R. Y., Samson C. M., Falk N. S., Chu D. S., Callanan D., Nguyen Q. D., Uveitis Study Group, Rose K., Haider A., and Di Padova F. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2, 52ra72 [PubMed]
34. Marshak-Rothstein A. (2006) Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823–835 [PubMed]
35. Mills K. H. (2011) TLR-dependent T-cell activation in autoimmunity. Nat. Rev. Immunol. 11, 807–822 [PubMed]
36. Conti F., Spinelli F. R., Alessandri C., and Valesini G. (2011) Toll-like receptors and lupus nephritis. Clin. Rev. Allergy Immunol. 40, 192–198 [PubMed]
37. Barton G. M., Kagan J. C., and Medzhitov R. (2006) Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7, 49–56 [PubMed]
38. Chauhan A. K., and Moore T. L. (2012) Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4(+) T-cells. Clin. Exp. Immunol. 167, 235–245 [PubMed]
39. Low J. M., Chauhan A. K., Gibson D. S., Zhu M., Chen S., Rooney M. E., Ombrello M. J., and Moore T. L. (2009) Proteomic analysis of circulating immune complexes in juvenile idiopathic arthritis reveals disease-associated proteins. Proteomics Clin. Appl. 3, 829–840 [PubMed]
40. Chauhan A. K., Chen C., Moore T. L., and DiPaolo R. J. (2015) Induced expression of FcγRIIIa (CD16a) on CD4+ T-cells triggers generation of IFN-γhigh subset. J. Biol. Chem. 290, 5127–5140 [PMC free article] [PubMed]
41. Schulz E. G., Mariani L., Radbruch A., and Höfer T. (2009) Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-γ and interleukin-12. Immunity 30, 673–683 [PubMed]
42. Annunziato F., Cosmi L., Liotta F., Maggi E., and Romagnani S. (2009) Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol. 5, 325–331 [PubMed]
43. Yao Z., Painter S. L., Fanslow W. C., Ulrich D., Macduff B. M., Spriggs M. K., and Armitage R. J. (1995) Human IL-17: a novel cytokine derived from T-cells. J. Immunol. 155, 5483–5486 [PubMed]
44. Aggarwal S., Ghilardi N., Xie M. H., de Sauvage F. J., and Gurney A. L. (2003) Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910–1914 [PubMed]
45. Cai G., Nie X., Zhang W., Wu B., Lin J., Wang H., Jiang C., and Shen Q. (2012) A regulatory role for IL-10 receptor signaling in development and B cell help of T follicular helper cells in mice. J. Immunol. 189, 1294–1302 [PubMed]
46. Parrish-Novak J., Dillon S. R., Nelson A., Hammond A., Sprecher C., Gross J. A., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper J. L., Kramer J., Conklin D., Presnell S. R., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant F. J., Lofton-Day C., Gilbert T., Rayond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly R. D., and Foster D. (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57–63 [PubMed]
47. Sandor M., and Lynch R. G. (1993) Lymphocyte Fc receptors: the special case of T-cells. Immunol. Today 14, 227–231 [PubMed]
48. Crispín J. C., Kyttaris V. C., Terhorst C., and Tsokos G. C. (2010) T-cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 317–325 [PMC free article] [PubMed]
49. LeibundGut-Landmann S., Gross O., Robinson M. J., Osorio F., Slack E. C., Tsoni S. V., Schweighoffer E., Tybulewicz V., Brown G. D., Ruland J., and Reis e Sousa C. (2007) Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8, 630–638 [PubMed]
50. Okazaki T., Maeda A., Nishimura H., Kurosaki T., and Honjo T. (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. U.S.A. 98, 13866–13871 [PubMed]
51. Patole P. S., Gröne H. J., Segerer S., Ciubar R., Belemezova E., Henger A., Kretzler M., Schlöndorff D., and Anders H. J. (2005) Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol. 16, 1326–1338 [PubMed]
52. Chen L., and Flies D. B. (2013) Molecular mechanisms of T-cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242 [PMC free article] [PubMed]
53. Enyedy E. J., Nambiar M. P., Liossis S. N., Dennis G., Kammer G. M., and Tsokos G. C. (2001) Fc epsilon receptor type I γ chain replaces the deficient T-cell receptor ζ chain in T-cells of patients with systemic lupus erythematosus. Arthritis Rheum. 44, 1114–1121 [PubMed]
54. Maddur M. S., Vani J., Hegde P., Lacroix-Desmazes S., Kaveri S. V., and Bayry J. (2011) Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 127, 823–830 [PubMed]
55. Pasare C., and Medzhitov R. (2003) Toll pathway-dependent blockade of CD4+CD25+ T-cell-mediated suppression by dendritic cells. Science 299, 1033–1036 [PubMed]
56. Schenten D., Nish S. A., Yu S., Yan X., Lee H. K., Brodsky I., Pasman L., Yordy B., Wunderlich F. T., Brüning J. C., Zhao H., and Medzhitov R. (2014) Signaling through the adaptor molecule MyD88 in CD4+ T-cells is required to overcome suppression by regulatory T-cells. Immunity 40, 78–90 [PMC free article] [PubMed]
57. Veldhoen M., Hocking R. J., Atkins C. J., Locksley R. M., and Stockinger B. (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T-cells. Immunity 24, 179–189 [PubMed]
58. Vogelpoel L. T., Hansen I. S., Rispens T., Muller F. J., van Capel T. M., Turina M. C., Vos J. B., Baeten D. L., Kapsenberg M. L., de Jong E. C., and den Dunnen J. (2014) Fc γ receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat. Commun. 5, 5444. [PMC free article] [PubMed]
59. Rittirsch D., Flierl M. A., Day D. E., Nadeau B. A., Zetoune F. S., Sarma J. V., Werner C. M., Wanner G. A., Simmen H. P., Huber-Lang M. S., and Ward P. A. (2009) Cross-talk between TLR4 and Fcγ receptor III (CD16) pathways. PLoS Pathog. 5, e1000464. [PMC free article] [PubMed]
60. Shahinian A., Pfeffer K., Lee K. P., Kündig T. M., Kishihara K., Wakeham A., Kawai K., Ohashi P. S., Thompson C. B., and Mak T. W. (1993) Differential T-cell costimulatory requirements in CD28-deficient mice. Science 261, 609–612 [PubMed]
61. Datta S. K., Kaliyaperumal A., Mohan C., and Desai-Mehta A. (1997) T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Lupus 6, 333–336 [PubMed]
62. Nurieva R. I., Liu X., and Dong C. (2011) Molecular mechanisms of T-cell tolerance. Immunol. Rev. 241, 133–144 [PMC free article] [PubMed]
63. Krishnan S., Nambiar M. P., Warke V. G., Fisher C. U., Mitchell J., Delaney N., and Tsokos G. C. (2004) Alterations in lipid raft composition and dynamics contribute to abnormal T-cell responses in systemic lupus erythematosus. J. Immunol. 172, 7821–7831 [PubMed]
64. Deng G. M., and Tsokos G. C. (2008) Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J. Immunol. 181, 4019–4026 [PMC free article] [PubMed]
65. Jury E. C., Isenberg D. A., Mauri C., and Ehrenstein M. R. (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T-cells from patients with systemic lupus erythematosus. J. Immunol. 177, 7416–7422 [PubMed]
66. Crow M. K. (2014) Type I interferon in the pathogenesis of lupus. J. Immunol. 192, 5459–5468 [PMC free article] [PubMed]
67. Phan T. G., Green J. A., Gray E. E., Xu Y., and Cyster J. G. (2009) Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat. Immunol. 10, 786–793 [PMC free article] [PubMed]
68. Heesters B. A., Chatterjee P., Kim Y. A., Gonzalez S. F., Kuligowski M. P., Kirchhausen T., and Carroll M. C. (2013) Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 38, 1164–1175 [PMC free article] [PubMed]
69. Latour S., Chow L. M., and Veillette A. (1996) Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases. J. Biol. Chem. 271, 22782–22790 [PubMed]
70. Mócsai A., Ruland J., and Tybulewicz V. L. (2010) The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387–402 [PMC free article] [PubMed]
71. Jones B., and Chen J. (2006) Inhibition of IFN-γ transcription by site-specific methylation during T helper cell development. EMBO J. 25, 2443–2452 [PubMed]
72. Amarilyo G., Lourenço E. V., Shi F. D., and La Cava A. (2014) IL-17 promotes murine lupus. J. Immunol. 193, 540–543 [PubMed]
73. Karonitsch T., Feierl E., Steiner C. W., Dalwigk K., Korb A., Binder N., Rapp A., Steiner G., Scheinecker C., Smolen J., and Aringer M. (2009) Activation of the interferon-γ signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum. 60, 1463–1471 [PubMed]
74. Vermeire K., Heremans H., Vandeputte M., Huang S., Billiau A., and Matthys P. (1997) Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J. Immunol. 158, 5507–5513 [PubMed]
75. Means T. K., Latz E., Hayashi F., Murali M. R., Golenbock D. T., and Luster A. D. (2005) Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115, 407–417 [PMC free article] [PubMed]
76. Mullen A. C., High F. A., Hutchins A. S., Lee H. W., Villarino A. V., Livingston D. M., Kung A. L., Cereb N., Yao T. P., Yang S. Y., and Reiner S. L. (2001) Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292, 1907–1910 [PubMed]
77. van Egmond M., Vidarsson G., and Bakema J. E. (2015) Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity. Immunol. Rev. 268, 311–327 [PubMed]
78. Iwasaki A., and Medzhitov R. (2010) Regulation of adaptive immunity by the innate immune system. Science 327, 291–295 [PMC free article] [PubMed]
79. Gelman A. E., Zhang J., Choi Y., and Turka L. A. (2004) Toll-like receptor ligands directly promote activated CD4+ T-cell survival. J. Immunol. 172, 6065–6073 [PMC free article] [PubMed]
80. Liu H., Komai-Koma M., Xu D., and Liew F. Y. (2006) Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T-cells. Proc. Natl. Acad. Sci. U.S.A. 103, 7048–7053 [PubMed]
81. Caron G., Duluc D., Frémaux I., Jeannin P., David C., Gascan H., and Delneste Y. (2005) Direct stimulation of human T-cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T-cells. J. Immunol. 175, 1551–1557 [PubMed]
82. Leadbetter E. A., Rifkin I. R., Hohlbaum A. M., Beaudette B. C., Shlomchik M. J., and Marshak-Rothstein A. (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603–607 [PubMed]
83. Funderburg N., Luciano A. A., Jiang W., Rodriguez B., Sieg S. F., and Lederman M. M. (2008) Toll-like receptor ligands induce human T-cell activation and death, a model for HIV pathogenesis. PLoS ONE 3, e1915. [PMC free article] [PubMed]
84. Ivanov S., Dragoi A. M., Wang X., Dallacosta C., Louten J., Musco G., Sitia G., Yap G. S., Wan Y., Biron C. A., Bianchi M. E., Wang H., and Chu W. M. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110, 1970–1981 [PubMed]
85. Zhang Y., Jones M., McCabe A., Winslow G. M., Avram D., and MacNamara K. C. (2013) MyD88 signaling in CD4 T-cells promotes IFN-γ production and hematopoietic progenitor cell expansion in response to intracellular bacterial infection. J. Immunol. 190, 4725–4735 [PMC free article] [PubMed]
86. Leifer C. A., Kennedy M. N., Mazzoni A., Lee C., Kruhlak M. J., and Segal D. M. (2004) TLR9 is localized in the endoplasmic reticulum before stimulation. J. Immunol. 173, 1179–1183 [PMC free article] [PubMed]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology